LIS
CRSP icon

Legacy Investment Solutions’s CRISPR Therapeutics CRSP Stock Holding History

Legacy Investment Solutions’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$195 Buy
+4
New +$155 ﹤0.01% 708
2024
Q4 		$159 Hold
4
– – ﹤0.01% 721
2024
Q3 		$200 Buy
+4
New +$203 ﹤0.01% 668

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Legacy Investment Solutions's CRSP Position: Q2 2025 in Review

Legacy Investment Solutions opened a new position in CRISPR Therapeutics (CRSP) in Q2 2025: 4 shares worth $195. The stake represents ﹤0.01% of the portfolio and ranks #708 among its holdings. This is a return to the name: Legacy Investment Solutions previously reported a position in CRSP as recently as Q4 2024.

Legacy Investment Solutions first reported a position in CRSP in Q3 2024 and has held it in 3 quarters since. The position peaked at $200 in Q3 2024. 433 funds tracked by Wall St. Rank hold CRSP as of Q2 2025.

  • Legacy Investment Solutions held 4 shares of CRISPR Therapeutics worth $195 as of Q2 2025.
  • CRISPR Therapeutics was a new Legacy Investment Solutions position in Q2 2025.
  • CRISPR Therapeutics made up ﹤0.01% of Legacy Investment Solutions's portfolio in Q2 2025, its #708 holding.
  • Legacy Investment Solutions first reported a position in CRISPR Therapeutics in Q3 2024 and has held it in 3 quarters since.
  • Legacy Investment Solutions's CRISPR Therapeutics position peaked at $200 in Q3 2024.
  • 433 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2025.

Based on Legacy Investment Solutions's 13F filing for Q2 2025, filed 6 Aug 2025.